EVALUATION OF ELABELA LEVELS IN OBESE INDIVIDUALS

Abstract

Aim: Obesity is a condition that occurs as a result of excessive weight gain. Obesity is related with the high risk of several diseases like cardiovascular diseases and diabetes mellitus. Elabela is a peptide that has emerged recently and is known to affect food intake by binding to apelinergic receptors. This study aimed to investigate the serum levels of Elabela in obese and non-obese individuals. Material and methods: This study involved 24 people with obesity and 25 healthy adult people as control group. Height, weight, gender, age, waist-hip circumference, blood pressure of participants were recorded and routine blood tests were measured. Serum concentrations of Elabela were determined using enzyme-linked immunosorbent assay. Results: When comparing the obese group to the controls, no statistically significant differences were observed between the two groups in terms of diastolic blood pressure, blood urea nitrogen, creatinine, total cholesterol, low density lipoprotein cholesterol and C-reactive protein. Similarly, both groups did not differ statistically regarding Elabela levels. The obese group exhibited significantly elevated levels of body mass index, waist/hip ratio, systolic blood pressure values, glucose, aspartate aminotransferase, alanine aminotransferase, triglyceride, insulin, homeostatic model assessment for insulin resistance (HOMA-IR) compared to the control group. The obese group demonstrated a significantly lower level of high-density lipoprotein cholesterol in comparison to the control group. Conclusions: In this study, it was found that there was no relationship between Elabela levels and obesity. However, this issue needs to be supported by further studies to clarify.